Beckman Coulter Logo

Boost speed, accuracy and efficiency

Mass spectrometry is rapidly evolving in the microbiology laboratory. The DxM Trio brings together the accuracy of the DxM MicroScan WalkAway system, the speed of mass spectrometry with the Bruker MALDI Biotyper® system and the efficiency of LabPro-MBT software. Together, this unique integration of technologies streamlines processes to enhance overall performance.

Bruker MALDI Biotyper

Receive microbial identification results within minutes.

  • Identify isolates rapidly with industry leading MALDI-TOF technology
  • Identify a wide range of microorganisms cost-effectively and with high accuracy
  • Save time and streamline workflow through clinically relevant libraries

DxM MicroScan WalkAway

Gain reliable, industry-trusted accuracy in the detection of critical antimicrobial resistance.

  • Detect emerging resistance for the toughest pathogens, including ESBL, MRSA, VRSA, VISA and VRE
  • Expand patient care options with the fewest clinically significant reporting limitations of the major automated ID/AST systems*
  • Reduce labor and material costs with fewer confirmatory and repeat tests*


View comprehensive ID and AST results from the Bruker MALDI Biotyper and DxM MicroScan Walkaway conveniently within LabPro-MBT.

  • Eliminate data transfers, potentially reducing errors
  • Gain efficiency by consolidating reporting of ID and AST data
  • Streamline data through a single LIS connection for both ID and AST results

Advance patient care with the DxM Trio

Fill out the form today to start the conversation.

I consent to receiving information:

Consent indicates that you would like to receive information about Beckman Coulter webinars, products, goods and services, including similarly related products, goods, or services from affiliate companies in the Danaher group.

By submitting your information you agree to Beckman Coulter storing your data in accordance with our Privacy Policy. Please review the Beckman Coulter Terms of Use and Privacy Policy where we explain what personal data we collect, use and share that you provide on our websites and other digital channels. If you do not agree with the collection and storage of your personal data please email Beckman Coulter at

*The assessment of clinically significant limitations is based upon a tabulation of CLSI Group A and B test and report recommendations published in the M100 guidance documents (excluding species with natural resistance) and 1st and 2nd drugs of choice published in The Medical Letter‘s Handbook of Antimicrobial Therapy, compared with the related FDA 510K summaries, device manufacturer‘s package inserts and product recall information. M100-S17, 2017.

MALDI Biotyper is the property of Bruker Daltonik GmbH.


© 2019 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.